Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun.
about
Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritisThe neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseasesPituitary Adenylate Cyclase-Activating Polypeptide Reverses Ammonium Metavanadate-Induced Airway Hyperresponsiveness in RatsDiverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway.VIP and PACAP38 modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines.Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor.Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.Vasoactive intestinal peptide-deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid-induced colitis.Effects of carvedilol treatment on cardiac cAMP response element binding protein expression and phosphorylation in acute coxsackievirus B3-induced myocarditisVasoactive intestinal peptide signaling axis in human leukemia.Characterisation of the mouse vasoactive intestinal peptide receptor type 2 gene, Vipr2, and identification of a polymorphic LINE-1-like sequence that confers altered promoter activity.Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages.Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: immunomodulation by the cAMP-PKA pathwayVPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.VIP and CRF reduce ADAMTS expression and function in osteoarthritis synovial fibroblasts.Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.Cyclic AMP: a selective modulator of NF-κB action.Transcriptional modulation by VIP: a rational target against inflammatory disease.The role of regulatory T cells in neurodegenerative diseases.Vasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1.Docosahexaenoic acid differentially affects TNFα and IL-6 expression in LPS-stimulated RAW 264.7 murine macrophages.Neuropeptides and Microglial Activation in Inflammation, Pain, and Neurodegenerative DiseasesVasoactive intestinal peptide enhances TNF-α-induced IL-6 and IL-8 synthesis in human proximal renal tubular epithelial cells by NF-κB-dependent mechanism.The ceramide-1-phosphate analogue PCERA-1 modulates tumour necrosis factor-alpha and interleukin-10 production in macrophages via the cAMP-PKA-CREB pathway in a GTP-dependent manner.Impairment of TNF-alpha production and action by imidazo[1,2- alpha] quinoxalines, a derivative family which displays potential anti-inflammatory properties.Effect of pituitary adenylate cyclase-activating polypeptide (PACAP) on IL-6, IL-8, and MCP-1 expression in human retinal pigment epithelial cell line.High molecular weight hyaluronic acid regulates MMP13 expression in chondrocytes via DUSP10/MKP5.Lipopolysaccharide stimulation of ERK1/2 increases TNF-alpha production via Egr-1.beta-adrenergic agonists exert their "anti-inflammatory" effects in monocytic cells through the IkappaB/NF-kappaB pathway.Adrenomedullin suppresses interleukin-1beta-induced tumor necrosis factor-alpha production in Swiss 3T3 cells.Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation.Vasoactive intestinal peptide prevents PKCε-induced intestinal epithelial barrier disruption during EPEC infection.VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts.Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro and in vivo.Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.Administration of a vasoactive intestinal peptide antagonist significantly enhances the autologous anti-leukemia T cell response in a murine model of AML.Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP.Induction of cyclooxygenase-2 by heat shock protein 60 in macrophages and endothelial cells.Inhibition of constitutive TNF production is associated with PACAP-mediated differentiation in PC12 cells
P2860
Q24795258-89CCE94F-43CE-43E7-941A-E31C424D4DC3Q26851670-735295D3-0D51-450F-990B-1286852C012EQ28647317-5B736938-216F-41D3-937A-43A3057A541DQ33797156-449C5775-DB0F-4422-8293-7BC5E84FFF48Q33838543-31D0F146-F84F-434A-903E-90EC163F0D83Q33894893-83338127-9F4B-4FE9-BAF0-3B9196E45F1BQ34238010-3D41C964-3E18-4B85-B7EA-4ADC2A3005B9Q34979549-C1E1983D-5971-4833-9C56-97F40C690261Q35041811-1F5A486C-4144-4A79-86CA-857584B33B8FQ35103939-3C9993B4-65E6-4DF2-A6CE-7572155BA9C3Q35648983-1DDCC9F3-F6B1-4CEF-A15A-79F37193ED67Q35893267-AC0B460D-B653-456B-A46E-B140917877BFQ36342098-6F6F6FD9-445B-4B7C-872E-9F6E7318133DQ37054934-D3384810-9B08-4404-8A78-F2FA29FB0733Q37447842-B123BAE6-C1FF-4115-A294-1E3D3E1D8FDBQ37552024-82450021-938A-482F-AAD2-B8AB9356E3D6Q37899788-D163DEE7-BE6D-4751-A5C8-5FF64CFFA2C9Q38019158-CDA8C26B-741F-4BA5-8E58-6DA9BA8F6294Q38035240-3AD7CFEB-4ED1-4CA7-BAEB-138FF92374A0Q38319884-3580926D-0839-4C8F-AAA9-7E27E604E764Q38881211-0F97612B-0F8E-4A6F-A134-1AD624D6B1B5Q39116758-77915355-7E4E-4BB7-B5E0-B98DA776008AQ39420647-35D7C719-67E1-4CE8-A1EA-91661A16E73DQ39773317-21ED87DC-37D5-48F8-8825-E79871A1F07AQ40222865-8FAECB77-2B77-4292-88A7-6331ACE35A30Q40340052-2E7D13D4-D133-4FAC-8E50-3DDEE1F2D4B8Q40705143-30E02194-DE18-4828-A4B2-A4ED852656E6Q40733506-106ED776-1D92-46AA-89C4-D9ECB71DAAEBQ40853258-6B2BD2DA-B2AC-4ED1-9B3D-BB8478E92A42Q40911459-99220681-5C10-41BC-B194-195E51771231Q40920235-A95FFCA1-C7B1-4D46-8971-7FA7714623DCQ41602366-402C49A0-707D-4D7C-881B-048F5A0B3820Q42487146-EEDACEBE-5E7A-4920-959E-99B5B8AA9C0AQ43949268-9590BCA1-94F5-49D2-AF1E-73F06663EDE8Q44060393-6B91BF6F-D84D-4D0B-8C82-52C3000B5F52Q45907183-B2DC8383-7B20-438F-90D4-87380B3C4FE5Q46460985-5A5CEDE3-4CB1-4CE4-BC28-C66B7AEE282FQ54447032-EB41C411-5CC2-497A-BB4B-B96A2DE77076Q57983833-83D03754-C472-484D-9793-939968887B9D
P2860
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Vasoactive intestinal peptide ...... element-binding protein/c-Jun.
@en
type
label
Vasoactive intestinal peptide ...... element-binding protein/c-Jun.
@en
prefLabel
Vasoactive intestinal peptide ...... element-binding protein/c-Jun.
@en
P2093
P2860
P356
P1476
Vasoactive intestinal peptide ...... element-binding protein/c-Jun.
@en
P2093
Brenneman DE
Gomariz RP
Munoz-Elias EJ
P2860
P304
31427-31436
P356
10.1074/JBC.273.47.31427
P407
P577
1998-11-01T00:00:00Z